ArticleNPJ breast cancer2022

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.

Julia Foldi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.